to Acquire Multi-National Medical Cannabis Producer “Better” Marking the First Major Consolidation in Pharmaceutical Grade Medical Cannabis Market
Acquisition is Expected to be Accretive
Strengthen InterCure’s Position as the Largest Cannabis Company Outside of North America
NEW YORK and TORONTO and HERZLIYA, Israel, Feb. 16, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced it has signed a definitive agreement (the "Agreement") with Cann Pharmaceutical Ltd. (“Better”), a pioneering Israeli medical cannabis multi-national operator known as “Better”. Under the terms of the agreement, InterCure will acquire 100% of Better’s shares, which includes “Better’s” unique strains, cultivation site, intellectual property, and commercial operations in Israel as well it’s international activities.
InterCure Signs Definitive Agreement to Acquire Multi-National Medical Cannabis Producer “Better”